NBI-1117569 / Neurocrine, Nxera Pharma - LARVOL DELTA

Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2025 (GlobeNewswire) - "Neurocrine Biosciences, Inc. outlined clinical development plans for the partnered muscarinic agonist portfolio in 2025, including Initiation of Phase 3 registrational studies with NBI-1117568 (an oral, muscarinic M4-selective agonist) in schizophrenia in 1H 2025; Initiation of a Phase 2 study with NBI-1117568 in bipolar mania in 2H 2025; Initiation of a Phase 2 study with NBI-1117570 (a dual M1 / M4 agonist) in schizophrenia in 2H 2025; Data readouts for NBI-1117570, NBI-1117567 (M1-preferring), and NBI-1117569 (M4-preferring) expected in 2025, all of which are being advanced in Phase 1 trials targeting neurological and neuropsychiatric conditions."

Clinical data • New P2 trial • New P3 trial • CNS Disorders • Schizophrenia